潰瘍性大腸炎 (ELEVATE) の誘導および維持療法としてのエトラシモド: ランダム化,ダブルブラインド,プラセボ対照,第3相試験
William J Sandborn1, Séverine Vermeire2, Laurent Peyrin-Biroulet3
1Division of Gastroenterology, University of California San Diego, La Jolla, CA, USA.
Lancet (London, England)
|March 5, 2023
まとめ
エトラシモドは,第3相試験において,潰瘍性大腸炎患者の臨床寛解に有意な効果を示した. このスフィンゴシン1リン酸受容体調節器は 中等から重度の病気の治療に 期待できる新しい治療法です
科学分野:
- 免疫学
- 胃腸内科
- 薬理学について
背景:
- エトラシモドは,S1Pサブタイプ1,4,5を標的とした経口スフィンゴシン1-リン酸 (S1P) 受容体調節剤です.
- 潰瘍性大腸炎 (UC) を含む免疫媒介疾患に対して開発中である.
研究 の 目的:
- 中度から重度の活発な潰瘍性大腸炎の成人の患者におけるエトラシモドの安全性と有効性を評価する.
- エトラシモドの誘導療法と維持療法の両方の有効性を評価する.
主な方法:
- 2つの独立したランダム化,ダブルブラインド,プラセボ対照のフェーズ3試験 (ELEVATE UC 52とELEVATE UC 12) が実施されました.
- 中度から重度のUCを持つ成人は,毎日経口エトラシモド (2 mg) またはプラセボを投与された.
- 主要評価項目は,12週と52週での臨床寛解率でした.
主要な成果:
- エトラシモドは,両方の試験で12週後にプラセボと比較して臨床寛解率を有意に増加させた (ELEVATE UC 52: 27% vs 7%; ELEVATE UC 12: 25% vs 15%).
- ELEVATE UC 52では,52週間で持続的な寛解が観察された (32%対7%).
- エトラシモド群では有害事象の発生率が高かったが,死亡や悪性腫瘍は報告されなかった.
結論:
- エトラシモドは,中等から重度の潰瘍性大腸炎の誘導および維持のための効果的でよく耐える治療法です.
- これはUCの管理における満たされていないニーズに対応する新しい治療の選択肢です.
関連する概念動画
Drugs for Treatment of Ulcerative Colitis in IBD
207
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
207
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
225
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
225
Drugs for Treatment of Diarrhea-Predominant IBS
252
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
252
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
180
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
180
Inflammatory Bowel Disease IV: Pharmacological Management
167
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
167
Drugs for Treatment of Constipation-Predominant IBS
266
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
266


